Literature DB >> 20809906

Local retinal sensitivity in relation to specific retinopathy lesions in diabetic macular oedema.

Wael Soliman1, Pascal Hasler, Birgit Sander, Michael Larsen.   

Abstract

PURPOSE: To study microperimetric macular sensitivity in diabetic macular oedema (DMO) in relation to lesion characteristics obtained by optical coherence tomography (OCT), colour fundus photography, and fluorescein angiography (FA).
METHODS: The study comprised 20 eyes in 15 patients with nonproliferative diabetic retinopathy and recently diagnosed untreated DMO. Investigations included microperimetry, fluorescein angiography, colour fundus photography, and OCT. All measures and gradings were made for each of the nine fields of an early treatment diabetic retinopathy study macula template. Statistical analysis was made using Spearman's nonparametric test including field and mean values within fields. Comparisons were made within the study population and with a normative microperimetry database.
RESULTS: Subnormal microperimetric sensitivity was associated with cystoid macular oedema, both in foveal petaloid (r = -0.50, p = 0.02) and extrafoveal honeycomb patterns (r = -0.8, p < 0.0001) and with outer nuclear layer cysts (r = -0. 5, p = 0.024), inner nuclear layer cysts (r = -0.31, p = 0.03), and hard exudate (r = -0.38, p = 0.0026). There was no detectable effect of focal noncystoid oedema (r = -0.16, p = 0. 48), diffuse noncystoid oedema (r = -0.14, p = 0.55), capillary nonperfusion (r = -0.33, p = 0.15), intraretinal haemorrhage (r = -0.15, p = 0.53), or serous retinal detachment (r = -0.11, p = 0.63). Foveal thickening was associated with locally reduced sensitivity (r = -0.54, p = 0.01). Foveal sensitivity was positively correlated to the visual acuity, with a correlation of 0.44 and a borderline significance (p = 0.0509).
CONCLUSIONS: Macular hard exudates and cystoid oedema were associated with locally reduced sensitivity. Thus, the lesions associated with reduced sensitivity for a white-on-white stimulus were such lesions that cause light to be blocked or scattered before it reaches the photoreceptors, suggesting that optical effects are a major cause of sensitivity loss.
© 2010 The Authors. Journal compilation © 2010 Acta Ophthalmol.

Entities:  

Mesh:

Year:  2010        PMID: 20809906     DOI: 10.1111/j.1755-3768.2010.01912.x

Source DB:  PubMed          Journal:  Acta Ophthalmol        ISSN: 1755-375X            Impact factor:   3.761


  5 in total

Review 1.  Psychophysical Exams as Early Indicators of Diabetic Retinopathy.

Authors:  Nicola Pescosolido; Giuseppe Buomprisco
Journal:  Eur Endocrinol       Date:  2014-02-28

2.  Intravitreal pegaptanib sodium (Macugen®) for treatment of diabetic macular oedema: a morphologic and functional study.

Authors:  Michele Rinaldi; Flavia Chiosi; Roberto dell'Omo; Mario R Romano; Francesco Parmeggiani; Francesco Semeraro; Rodolfo Mastropasqua; Ciro Costagliola
Journal:  Br J Clin Pharmacol       Date:  2012-12       Impact factor: 4.335

3.  Quantitative evaluation of hard exudates in diabetic macular edema by multicolor imaging and their associations with serum lipid levels.

Authors:  Ruowen Gong; Ruyi Han; Jingli Guo; Wei Liu; Gezhi Xu
Journal:  Acta Diabetol       Date:  2021-04-02       Impact factor: 4.280

4.  MULTISCALE CORRELATION OF MICROVASCULAR CHANGES ON OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY WITH RETINAL SENSITIVITY IN DIABETIC RETINOPATHY.

Authors:  Emily S Levine; Eric M Moult; Eugenia Custo Greig; Yi Zhao; Varsha Pramil; Isaac Gendelman; Agha Y Alibhai; Caroline R Baumal; Andre J Witkin; Jay S Duker; James G Fujimoto; Nadia K Waheed
Journal:  Retina       Date:  2022-02-01       Impact factor: 4.256

5.  Diabetic vascular hyperpermeability: optical coherence tomography angiography and functional loss assessments of relationships among retinal vasculature changes.

Authors:  Mitsuru Arima; Shintaro Nakao; Yoshihiro Kaizu; Iori Wada; Muneo Yamaguchi; Kohta Fujiwara; Masato Akiyama; Alan W Stitt; Koh-Hei Sonoda
Journal:  Sci Rep       Date:  2021-02-18       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.